Merck & Co Inc
XSGO : MRKFinancials
Income statement · full history
USD in millions · per-share amounts unscaled. Each period shows the value from the latest filing that prints it.
| Reported line item | Jan 1, 2017 to Dec 31, 2017 | Jan 1, 2018 to Dec 31, 2018 | Jan 1, 2019 to Dec 31, 2019 | Jan 1, 2020 to Dec 31, 2020 | Jan 1, 2021 to Dec 31, 2021 | Jan 1, 2022 to Dec 31, 2022 | Jan 1, 2023 to Dec 31, 2023 | Jan 1, 2024 to Dec 31, 2024 | Jan 1, 2025 to Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 40,122 | 42,294 | 39,121R | 41,518R | 48,704 | 59,283 | 60,115 | 64,168 | 65,011 |
| Cost of sales | 12,912 | 13,509 | 12,016R | 13,618R | 13,626 | 17,411 | 16,126 | 15,193 | 16,382 |
| Selling, general and administrative | 10,074R | 10,102 | 9,455R | 8,955R | 9,634 | 10,042 | 10,504 | 10,816 | 10,733 |
| Research and development | 10,339R | 9,752 | 9,724R | 13,397R | 12,245 | 13,548 | 30,531 | 17,938 | 15,789 |
| Restructuring costs | 776 | 632 | 626R | 575R | 661 | 337 | 599 | 309 | 889 |
| Other (income) expense, net | (500)R | (402) | 129R | (890)R | (1,341) | 1,501 | 466 | (24) | 151 |
| Total costs, expenses and other | 33,601 | 33,593 | 31,950R | 35,655R | 34,825 | 42,839 | 58,226 | 44,232 | 43,944 |
| Income Before Taxes | 6,521 | 8,701 | 7,171R | 5,863R | 13,879 | 16,444 | 1,889 | 19,936 | 21,067 |
| Taxes on Income | 4,103 | 2,508 | 1,565R | 1,340R | 1,521 | 1,918 | 1,512 | 2,803 | 2,804 |
| Net Income | 2,418 | 6,193 | 5,606R | 4,523R | 12,358 | 14,526 | 377 | 17,133 | 18,263 |
| Less: Net Income Attributable to Noncontrolling Interests | (84) | 4 | 13 | 7 | 12 | 16 | 9 | ||
| Less: Net Income (Loss) Attributable to Noncontrolling Interestsno longer reported | 24 | (27) | (66) | 15 | |||||
| Net Income Attributable to Merck & Co., Inc. | 2,394 | 6,220 | 9,843 | 7,067 | 13,049 | 14,519 | 365 | 17,117 | 18,254 |
| Net Income from Continuing Operations Attributable to Merck & Co., Inc.no longer reported | 5,690 | 4,519 | 12,345 | 14,519 | 365 | ||||
| Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | 0.88 | 2.34 | 3.84 | 2.79 | 5.16 | 5.73 | 0.14 | 6.76 | 7.30 |
| Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interestsno longer reported | 4,153 | 2,548 | 704 | 0 | 0 | ||||
| Income from Continuing Operations (in dollars per share)no longer reported | 2.22 | 1.79 | 4.88 | 5.73 | 0.14 | ||||
| Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | 0.87 | 2.32 | 3.81 | 2.78 | 5.14 | 5.71 | 0.14 | 6.74 | 7.28 |
| Income from Discontinued Operations (in dollars per share)no longer reported | 1.62 | 1.01 | 0.28 | 0.00 | 0.00 | ||||
| Income from Continuing Operations (in dollars per share)no longer reported | 2.21 | 1.78 | 4.86 | 5.71 | 0.14 | ||||
| Income from Discontinued Operations (in dollars per share)no longer reported | 0.28 | 0.00 | 0.00 | ||||||
| Income from Discontinued Operations (in dollars per share)no longer reported | 1.61 | 1.00 | 0.28 | 0.00 |
History starts FY2017, the period ended Dec 31, 2017 — the earliest period our structured-data source covers, not the company’s first year.
22 reported lines · 9 periods · values taken from the latest filing that prints each period.
- R23 restated by the filer — hover for the figure as first reported.
- italic16 from an earlier filing than the rest of the column.
- no longer reported8 lines the filer stopped printing.
- — the filer printed the line and left the period empty. An empty cell means the line was not printed at all; it is never a zero.
160 of 160 values link to the exact element in the filer’s own document.
Every line and every caption is the company’s own. Each period carries the value from the latest filing that prints it, which is why a restated period shows the restated number with the figure as first reported kept underneath.
Nothing on this table is computed by us: no fourth quarter, no growth rate, no margin. Marks describe the filer’s own restatements.